^
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
C3
SOHO 2022 - 6 days - (New C3)
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
ponatinib
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib
Sensitive
:
A1
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive
:
A1
CD19 positive
Acute Lymphocytic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
mercaptopurine
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
vincristine liposomal
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
recombinant Erwinia asparaginase
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
pegaspargase
Sensitive
:
A1
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
A1
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
dasatinib
Resistant
:
A2
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
dasatinib
Resistant
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
nilotinib
Sensitive
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
nilotinib
Resistant
:
A2
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2